Yale University

Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone.

TitleTipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone.
Publication TypeJournal Article
Year of Publication2011
AuthorsBruce, Douglas R., David E. Moody, Wenfang B. Fang, Diane Chodkowski, Laurie Andrews, and Gerald H. Friedland
JournalThe American journal of drug and alcohol abuse
Volume37
Issue4
Pagination224-8
Date Published2011 Jul
ISSN1097-9891
KeywordsAdult, Buprenorphine, Drug Interactions, Female, HIV Seronegativity, Humans, Male, Metabolic Detoxication, Drug, Middle Aged, Naloxone, Narcotic Antagonists, Opioid-Related Disorders, Pyridines, Pyrones, Ritonavir
AbstractPrevious reports on the pharmacokinetic of tipranavir (TPV) and buprenorphine (BUP)/ naloxone found that coadministration resulted in an 80% reduction in the area under the curve AUC of the primary BUP metabolite, norBUP, without any pharmacodynamic consequences. This study was conducted to characterize how tipranivir/ritonavir effects the glucuronide metabolites of BUP and may explain the reduction in the norBUP.
DOI10.1097/QAI.0b013e3181fbc94f
Alternate JournalAm J Drug Alcohol Abuse

External Links